• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. 
    •   QMRO Home
    • Blizard Institute
    • Centre for Neuroscience, Surgery and Trauma
    • Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis.
    •   QMRO Home
    • Blizard Institute
    • Centre for Neuroscience, Surgery and Trauma
    • Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis.
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis.

    View/Open
    Published version (5.516Mb)
    Volume
    1
    Pagination
    84 - ?
    DOI
    10.1186/2051-5960-1-84
    Journal
    Acta Neuropathol Commun
    Metadata
    Show full item record
    Abstract
    BACKGROUND: [corrected] Multiple Sclerosis has two clinical phases reflecting distinct but inter-related pathological processes: focal inflammation drives the relapse-remitting stage and neurodegeneration represents the principal substrate of secondary progression. In contrast to the increasing number of effective anti-inflammatory disease modifying treatments for relapse-remitting disease, the absence of therapies for progressive disease represents a major unmet clinical need. This raises the unanswered question of whether elimination of clinical relapses will prevent subsequent progression and if so how early in the disease course should treatment be initiated. Experimental autoimmune encephalomyelitis in the Biozzi ABH mouse recapitulates the clinical and pathological features of multiple sclerosis including relapse-remitting episodes with inflammatory mediated demyelination and progressive disability with neurodegeneration. To address the relationship between inflammation and neurodegeneration we used an auto-immune tolerance strategy to eliminate clinical relapses in EAE in a manner analogous to the clinical effect of disease modifying treatments. RESULTS: By arresting clinical relapses in EAE at two distinct stages, early and late disease, we demonstrate that halting immune driven demyelination even after the first major clinical event is insufficient to prevent long-term neurodegeneration and associated gliosis. Nonetheless, early intervention is partially neuroprotective, whereas later interventions are not. Furthermore early tolerisation is also associated with increased remyelination. CONCLUSIONS: These findings are consistent with both a partial uncoupling of inflammation and neurodegeneration and that the regenerative response of remyelination is negatively correlated with inflammation. These findings strongly support the need for early combinatorial treatment of immunomodulatory therapies and neuroprotective treatments to prevent long-term neurodegeneration in multiple sclerosis.
    Authors
    Hampton, DW; Serio, A; Pryce, G; Al-Izki, S; Franklin, RJ; Giovannoni, G; Baker, D; Chandran, S
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/18967
    Collections
    • Centre for Neuroscience, Surgery and Trauma [993]
    Language
    eng
    Licence information
    CC-BY
    Copyright statements
    © 2013 Hampton et al.; licensee BioMed Central Ltd.
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.